Pharmaceuticals

Ocrevus Market 2026–2030: Emerging Trends and Forecast Opportunities

March 6, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the ocrevus market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Ocrevus Market by the end of 2030?

Throughout the historic period, growth was propelled by an enhanced understanding of multiple sclerosis pathology, alongside the authorization of disease-modifying therapies. This expansion was further supported by the broader reach of neurology specialty care, an increase in MS diagnosis rates, and the widespread availability of biologic infusion infrastructure.

Anticipated expansion during the forecast period stems from the growing adoption of personalized MS treatment approaches, the broadening of home and outpatient infusion services, rising investments in neuroimmunology research, an increasing emphasis on slowing disease progression, and the development of next-generation monoclonal antibodies.

Key trends observed throughout the forecast period include the increasing utilization of monoclonal antibody therapies for MS, a rising adoption of B-cell targeted treatments, the expansion of infusion center-based care models, a growing focus on long-term disease modification, and enhanced patient monitoring alongside real-world evidence collection.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20321&type=smp

What Drivers Are Shaping Future Opportunities In The Ocrevus Market?

The growing incidence of multiple sclerosis is projected to fuel the expansion of the Ocrevus market. Multiple sclerosis (MS) is an ongoing autoimmune condition where the immune system erroneously attacks the central nervous system’s nerve fiber protection, known as the myelin sheath. The increase in MS diagnoses stems from various elements, including genetic predispositions, environmental influences, and lifestyle choices, alongside improved diagnostic capabilities, greater public awareness, and shifts in diet and urban living patterns. Ocrevus treats multiple sclerosis (MS) by targeting and diminishing CD20-positive B-cells, which are key contributors to the immune-driven harm in MS, thereby decreasing disease activity, slowing its progression, and managing associated symptoms. For example, as reported in May 2024 by the MS Society UK, a non-profit organization based in the UK, more than 150,000 individuals are affected by MS in the UK as of 2024. The disease’s occurrence has risen by 15% in England, 10% in Scotland, 9% in Northern Ireland, and 8% in Wales. Consequently, the increasing prevalence of multiple sclerosis is set to boost the Ocrevus market.

Which Segments Are Gaining Traction In The Ocrevus Market?

The ocrevus market covered in this report is segmented –

1) By Clinical Indications: Relapsing-Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis

2) By Formulation: Liquid Formulations, Tablet Or Capsule Formulation

3) By Route Of Administration: Oral, Injectable

4) By End User: Hospitals, Retail Pharmacies, Online Pharmacies

Which Trends Are Influencing The Performance And Direction Of The Ocrevus Market?

Major companies in the Ocrevus market are concentrating on developing innovative solutions, such as subcutaneous combination formulations. This effort aims to address the increasing demand for more convenient administration, improved treatment flexibility, and expanded access for multiple sclerosis patients. Subcutaneous formulations merge therapeutic monoclonal antibodies with absorption-enhancing agents, enabling quicker delivery and a reduced infusion burden compared to traditional intravenous dosing, which necessitates longer administration times in clinical settings. For instance, in September 2024, Genentech Inc., a US-based biotechnology company, announced that the United States Food and Drug Administration (U.S. FDA) had granted approval for Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for treating both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo is the first and only subcutaneous (SC) injection that healthcare professionals can administer twice a year, taking approximately 10 minutes per session. This significant approval provides individuals living with multiple sclerosis (MS) with more treatment options and offers healthcare providers greater flexibility to tailor care to meet the unique needs of each patient.

Who Are The Core Companies Influencing Trends In The Ocrevus Market?

Major companies operating in the ocrevus market are F. Hoffmann-La Roche Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/ocrevus-global-market-report

Which Regions Are Projected To Dominate The Ocrevus Market In The Coming Years?

North America was the largest region in the ocrevus market in 2025. The regions covered in the ocrevus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Ocrevus Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20321&type=smp

Browse Through More Reports Similar to the Global Ocrevus Market 2026, By The Business Research Company

White Inorganic Pigments Market Report 2026

https://www.thebusinessresearchcompany.com/report/white-inorganic-pigments-global-market-report

Oral Antidiabetic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-antidiabetic-drugs-global-market-report

Odbc Market Report 2026

https://www.thebusinessresearchcompany.com/report/odbc-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795